Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis.
Flurbiprofen has been compared with phenylbutazone in a double-blind study involving 33 patients with acute gout. Patients received either flurbiprofen 400 mg daily for 48 h followed by 200 mg daily, or phenylbutazone 800 mg daily for 48 h followed by 400 mg daily. The drugs were of comparable efficacy, while side-effects were uncommon and relatively mild. Flurbiprofen appears to be a satisfactory alternative to phenylbutazone in the management of acute gouty arthritis.
D000328:Adult; D000368:Aged; D001168:Arthritis / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005480:Flurbiprofen / Q000009:adverse effects / Q000627:therapeutic use*; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010653:Phenylbutazone / Q000009:adverse effects / Q000627:therapeutic use*; D011422:Propionates / Q000627:therapeutic use*; D011897:Random Allocation
D011422:Propionates; D005480:Flurbiprofen; D010653:Phenylbutazone